Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Total Non-Current Liabilities of $4.0 billion for Q1 2026, up 10.08% year-on-year from $3.7 billion in Q1 2025, and down 2.95% on a QoQ basis from $4.2 billion in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 17 years of Total Non-Current Liabilities data on file, last reported at $4.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 10.08% year-over-year to $4.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.0 billion (up 10.08% YoY), and the FY2025 full-year result was $4.2 billion, up 10.31% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $4.0 billion, down from $4.2 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.2 billion in Q3 2025 and bottomed at $2.9 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $3.7 billion (2024), against an average of $3.7 billion.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities advanced 29.54%; it then slipped 1.28% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $3.5 billion in 2022, then advanced by 7.16% to $3.7 billion in 2023, then climbed by 1.01% to $3.8 billion in 2024, then advanced by 10.31% to $4.2 billion in 2025, then slipped by 2.95% to $4.0 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.0 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.05 Bn |
| Dec 31, 2025 | 4.17 Bn |
| Sep 30, 2025 | 4.18 Bn |
| Jun 30, 2025 | 3.91 Bn |
| Mar 31, 2025 | 3.68 Bn |
| Dec 31, 2024 | 3.78 Bn |
| Sep 30, 2024 | 3.82 Bn |
| Jun 30, 2024 | 3.66 Bn |
| Mar 31, 2024 | 3.72 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.72 Bn |
| Jun 30, 2023 | 3.55 Bn |
| Mar 31, 2023 | 3.43 Bn |
| Dec 31, 2022 | 3.49 Bn |
| Sep 30, 2022 | 3.42 Bn |
| Jun 30, 2022 | 3.00 Bn |
| Mar 31, 2022 | 2.91 Bn |
| Dec 31, 2021 | 2.96 Bn |
| Sep 30, 2021 | 2.64 Bn |
| Jun 30, 2021 | 2.58 Bn |
| Mar 31, 2021 | 2.27 Bn |
| Dec 31, 2020 | 2.35 Bn |
| Sep 30, 2020 | 2.08 Bn |
| Jun 30, 2020 | 1.96 Bn |
| Mar 31, 2020 | 920.70 Mn |
| Dec 31, 2019 | 947.11 Mn |
| Sep 30, 2019 | 925.50 Mn |
| Jun 30, 2019 | 949.70 Mn |
| Mar 31, 2019 | 461.94 Mn |
| Dec 31, 2018 | 267.87 Mn |
| Sep 30, 2018 | 193.20 Mn |
| Jun 30, 2018 | 164.40 Mn |
| Mar 31, 2018 | 163.88 Mn |
| Dec 31, 2017 | 223.95 Mn |
| Sep 30, 2017 | 296.60 Mn |
| Jun 30, 2017 | 308.50 Mn |
| Mar 31, 2017 | 299.84 Mn |
| Dec 31, 2016 | 339.52 Mn |
| Sep 30, 2016 | 295.95 Mn |
| Jun 30, 2016 | 281.90 Mn |
| Mar 31, 2016 | 126.53 Mn |
| Dec 31, 2015 | 120.50 Mn |
| Sep 30, 2014 | 81.38 Mn |
| Jun 30, 2014 | 89.39 Mn |
| Mar 31, 2014 | 124.32 Mn |
| Sep 30, 2012 | 144.67 Mn |
| Mar 31, 2012 | 142.21 Mn |
| Dec 31, 2011 | 163.20 Mn |
| Sep 30, 2011 | 181.62 Mn |
| Jun 30, 2011 | 203.54 Mn |
| Mar 31, 2011 | 222.42 Mn |
| Dec 31, 2010 | 234.89 Mn |
| Jun 30, 2010 | 274.53 Mn |
| Dec 31, 2009 | 303.23 Mn |